or usual name of the drugs; Section 502 (f) (1), the repackaged *pentobarbital sodium capsules* and the *Dexedrine Sulfate tablets* failed to bear labeling containing adequate directions for use since the directions "1 capsule at bedtime when needed" and "one at bedtime as needed," borne on the labeling of the repackaged *pentobarbital sodium capsules*, and the directions "2 tablets each morning," borne on the labeling of the repackaged *Dexedrine Sulfate tablets*, were not adequate directions for use; and, Section 502 (f) (2), the labeling of the repackaged *sulfadiazine tablets* bore no warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration.

DISPOSITION: May 7, 1951. Pleas of guilty having been entered, the court imposed a fine of $135, plus costs, against the individual defendants jointly. No fine was imposed against the partnership.

3644. Misbranding of dextro-amphetamine sulfate (Dexedrine Sulfate) tablets. U. S. v. Physicians & Surgeons Apothecary & Surgical Supply Co., Inc., and Sam O'Neal and Sam S. Romano. Pleas of nolo contendere. Corporation fined $150; each individual defendant fined $50. (F. D. C. No. 31289. Sample Nos. 21411–L, 21414–L, 21423–L.)

INFORMATION FILED: December 21, 1951, Northern District of Alabama, against Physicians & Surgeons Apothecary & Surgical Supply Co., Inc., Birmingham, Ala., and Sam O'Neal, vice-president of the corporation, and Sam S. Romano, treasurer.

ALLEGED SHIPMENT: From the State of Pennsylvania into the State of Alabama, of quantities of *dextro-amphetamine sulfate* (*Dexedrine Sulfate*) *tablets*.

ALLEGED VIOLATION: On or about May 1, 2, and 5, 1951, while the drug was being held for sale after shipment in interstate commerce, the defendants caused various quantities of the drug to be repacked and sold without a physician's prescription, which acts resulted in the repackaged drug being misbranded.

NATURE OF CHARGE: Misbranding, Section 502 (b) (2), the repackaged drug failed to bear a label containing an accurate statement of the quantity of the contents since the label bore no statement of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drug failed to bear adequate directions for use since the labeling bore no directions for use.

DISPOSITION: January 10, 1952. Pleas of nolo contendere having been entered, the court imposed a fine of $150 against the corporation and $50 against each individual defendant.

3645. Misbranding of dextro-amphetamine sulfate (Dexedrine Sulfate) tablets. U. S. v. Goldstein's Pharmacy, Phillip Goldstein, and Sidney Schatz. Pleas of nolo contendere. Partnership fined $150; each individual defendant fined $50. (F. D. C. No. 31290. Sample Nos. 55077–K, 20751–L, 20767–L, 21415–L, 21427–L.)

INFORMATION FILED: December 18, 1951, Northern District of Alabama, against Goldstein's Pharmacy, a partnership, Ensley, Ala., and Phillip Goldstein, a partner, and Sidney Schatz, a pharmacist.

ALLEGED SHIPMENT: From the State of Pennsylvania into the State of Alabama, of quantities of *dextro-amphetamine sulfate* (*Dexedrine Sulfate*) *tablets*.